Jeffrey Edwards
Directeur/Membre du Conseil chez FIBROGEN, INC.
Fortune : 320 881 $ au 31/05/2024
Profil
Jeffrey L.
Edwards is currently an Independent Director at Bio-Rad Laboratories, Inc., Lifecore Biomedical, Inc., MAP Pharmaceuticals LLC, Viamet Pharmaceuticals, Inc., BioTheryX, Inc., Viamet Pharmaceuticals Corp., FibroGen, Inc., and Clearside Biomedical, Inc. He previously worked as the Chief Financial Officer & Executive VP-Finance at Allergan, Inc. from 2014 to 2015.
Before that, he was a Principal at Banque Paribas Belgique SA from 1992 to 1993 and at Security Pacific National Bank from 1983 to 1992.
He obtained his undergraduate degree from Muhlenberg College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/02/2024 | 49 667 ( 0,16% ) | 290 055 $ | 31/05/2024 | |
FIBROGEN, INC.
0,03% | 05/06/2024 | 25 688 ( 0,03% ) | 30 826 $ | 31/05/2024 |
Postes actifs de Jeffrey Edwards
| Sociétés | Poste | Début |
|---|---|---|
| FIBROGEN, INC. | Directeur/Membre du Conseil | 28/10/2015 |
| BIO-RAD LABORATORIES, INC. | Directeur/Membre du Conseil | 25/04/2017 |
| CLEARSIDE BIOMEDICAL, INC. | Directeur/Membre du Conseil | 26/09/2018 |
| LIFECORE BIOMEDICAL, INC. | Directeur/Membre du Conseil | 14/10/2020 |
Serica Technologies, Inc.
 Serica Technologies, Inc. Pharmaceuticals: MajorHealth Technology Serica Technologies, Inc. produces silk-based biomaterial products for tissue rejuvenation. The company develops knee ligament replacements from silk biomaterial. The company was founded on May 31, 2000 and is headquartered in Irvine, CA. | Directeur Financier/CFO | 25/04/2011 |
MAP Pharmaceuticals LLC
 MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Directeur/Membre du Conseil | 01/03/2013 |
Viamet Pharmaceuticals Corp.
 Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
Viamet Pharmaceuticals, Inc.
 Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Directeur/Membre du Conseil | - |
BioTheryX, Inc.
 BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Directeur/Membre du Conseil | 18/09/2019 |
Anciens postes connus de Jeffrey Edwards
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Jeffrey Edwards
| Muhlenberg College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| FIBROGEN, INC. | Health Technology |
| BIO-RAD LABORATORIES, INC. | Health Technology |
| CLEARSIDE BIOMEDICAL, INC. | Health Technology |
| LIFECORE BIOMEDICAL, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Allergan, Inc.
 Allergan, Inc. Pharmaceuticals: MajorHealth Technology Allergan, Inc. operated as a global healthcare company. It engaged in the development and commercialization of specialty pharmaceutical, medical device ,and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention, urological, and other specialty markets. The company was founded by Gavin S. Herbert Sr. in 1950 and headquartered in Irvine, CA. | Health Technology |
| Banque Paribas Belgique SA | Finance |
| Security Pacific National Bank | Finance |
Serica Technologies, Inc.
Serica Technologies, Inc. Pharmaceuticals: MajorHealth Technology Serica Technologies, Inc. produces silk-based biomaterial products for tissue rejuvenation. The company develops knee ligament replacements from silk biomaterial. The company was founded on May 31, 2000 and is headquartered in Irvine, CA. | Health Technology |
MAP Pharmaceuticals LLC
MAP Pharmaceuticals LLC Medical SpecialtiesHealth Technology MAP Pharmaceuticals, Inc. develops therapies and inhalation delivery technologies. The company was founded by Thomas A. Armer on July 3, 2003 and is headquartered in Irvine, CA. | Health Technology |
Viamet Pharmaceuticals Corp.
Viamet Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals Corp. engages in the discovery, development, and commercialization of novel pharmaceuticals based on its proprietary metalloenzyme chemistry and biology technology platform. Its clinical portfolio includes novel agents to treat chronic and life threatening fungal infections. Its products include VT-1161, an oral agent that treats onychomycosis; VT-1129, which treats cryptococcal meningitis; and VT-1598, that treats coccidioidomycosis. The company was founded by Herbert Holden Thorp and Thomas V. O'Halloran in December 2011 and is headquartered in Durham, NC. | Health Technology |
Viamet Pharmaceuticals, Inc.
Viamet Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Viamet Pharmaceuticals, Inc. discovers and develops inhibitors of validated metalloenzymes. The firm's clinical portfolio includes novel agents to treat both chronic and life threatening fungal infections. It also leverage our metalloenzyme expertise in other therapeutic areas including oncology and orphan diseases. The company was founded by Thomas V. O’Halloran and Holden H. Thorp on August 18, 2005 and is headquartered in Durham, NC. | Health Technology |
BioTheryX, Inc.
BioTheryX, Inc. Pharmaceuticals: MajorHealth Technology BioTheryX, Inc. pengages in the development of clinical drugs. It focuses on the restoration of protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition. The company was founded by David I. Stirling and Lawrence Zaslow in 2007 and is headquartered in Chappaqua, NY. | Health Technology |
